153 related articles for article (PubMed ID: 34261294)
1. mTOR inhibitors sensitize multiple myeloma cells to venetoclax via IKZF3- and Blimp-1-mediated BCL-2 upregulation.
Osada N; Kikuchi J; Koyama D; Kuroda Y; Yasui H; Leverson JD; Furukawa Y
Haematologica; 2021 Nov; 106(11):3008-3013. PubMed ID: 34261294
[No Abstract] [Full Text] [Related]
2. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.
Punnoose EA; Leverson JD; Peale F; Boghaert ER; Belmont LD; Tan N; Young A; Mitten M; Ingalla E; Darbonne WC; Oleksijew A; Tapang P; Yue P; Oeh J; Lee L; Maiga S; Fairbrother WJ; Amiot M; Souers AJ; Sampath D
Mol Cancer Ther; 2016 May; 15(5):1132-44. PubMed ID: 26939706
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma.
Algarín EM; Díaz-Tejedor A; Mogollón P; Hernández-García S; Corchete LA; San-Segundo L; Martín-Sánchez M; González-Méndez L; Schoumacher M; Banquet S; Kraus-Berthier L; Kloos I; Derreal A; Halilovic E; Maacke H; Gutiérrez NC; Mateos MV; Paíno T; Garayoa M; Ocio EM
Haematologica; 2020 Mar; 105(3):e116-e120. PubMed ID: 31320555
[No Abstract] [Full Text] [Related]
4. Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma.
Bajpai R; Sharma A; Achreja A; Edgar CL; Wei C; Siddiqa AA; Gupta VA; Matulis SM; McBrayer SK; Mittal A; Rupji M; Barwick BG; Lonial S; Nooka AK; Boise LH; Nagrath D; Shanmugam M
Nat Commun; 2020 Mar; 11(1):1228. PubMed ID: 32144272
[TBL] [Abstract][Full Text] [Related]
5. Targeting Bcl-2 for the treatment of multiple myeloma.
Touzeau C; Maciag P; Amiot M; Moreau P
Leukemia; 2018 Sep; 32(9):1899-1907. PubMed ID: 30076373
[TBL] [Abstract][Full Text] [Related]
6. Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma.
Algarín EM; Quwaider D; Campos-Laborie FJ; Díaz-Tejedor A; Mogollón P; Vuelta E; Martín-Sánchez M; San-Segundo L; González-Méndez L; Gutiérrez NC; García-Sanz R; Paíno T; De Las Rivas J; Ocio EM; Garayoa M
Cells; 2021 Mar; 10(3):. PubMed ID: 33806619
[TBL] [Abstract][Full Text] [Related]
7. Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax.
Matulis SM; Gupta VA; Nooka AK; Hollen HV; Kaufman JL; Lonial S; Boise LH
Leukemia; 2016 May; 30(5):1086-93. PubMed ID: 26707935
[TBL] [Abstract][Full Text] [Related]
8. Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression.
Gupta VA; Barwick BG; Matulis SM; Shirasaki R; Jaye DL; Keats JJ; Oberlton B; Joseph NS; Hofmeister CC; Heffner LT; Dhodapkar MV; Nooka AK; Lonial S; Mitsiades CS; Kaufman JL; Boise LH
Blood; 2021 Jul; 137(26):3604-3615. PubMed ID: 33649772
[TBL] [Abstract][Full Text] [Related]
9. Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence.
Kitadate A; Terao T; Narita K; Ikeda S; Takahashi Y; Tsushima T; Miura D; Takeuchi M; Takahashi N; Matsue K
Cancer Sci; 2021 Sep; 112(9):3645-3654. PubMed ID: 34288263
[TBL] [Abstract][Full Text] [Related]
10. Venetoclax for the treatment of multiple myeloma.
Vaxman I; Sidiqi MH; Gertz M
Expert Rev Hematol; 2018 Dec; 11(12):915-920. PubMed ID: 30428277
[No Abstract] [Full Text] [Related]
11. Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax.
Bajpai R; Matulis SM; Wei C; Nooka AK; Von Hollen HE; Lonial S; Boise LH; Shanmugam M
Oncogene; 2016 Jul; 35(30):3955-64. PubMed ID: 26640142
[TBL] [Abstract][Full Text] [Related]
12. Acute myeloid leukemia-driven IL-3-dependent upregulation of BCL2 in non-malignant hematopoietic stem and progenitor cells increases venetoclax-induced cytopenias.
Fowler-Shorten DJ; Maynard RS; Hampton K; Altera A; Markham M; Ehikioya M; Wojtowicz EE; Bowles KM; Rushworth SA; Hellmich C
Haematologica; 2024 May; 109(5):1576-1581. PubMed ID: 38186347
[No Abstract] [Full Text] [Related]
13. Profound response to venetoclax monotherapy in a patient with BCL-2 positive relapsed multiple myeloma and extramedullary CNS manifestations.
Cordas Dos Santos DM; Paul T; Kunz WG; Rudelius M; Theurich S
Leuk Lymphoma; 2022 Nov; 63(11):2706-2710. PubMed ID: 35793435
[No Abstract] [Full Text] [Related]
14. Venetoclax, bortezomib and S63845, an MCL1 inhibitor, in multiple myeloma.
Wong KY; Chim CS
J Pharm Pharmacol; 2020 May; 72(5):728-737. PubMed ID: 32066201
[TBL] [Abstract][Full Text] [Related]
15. Natural history of multiple myeloma patients refractory to venetoclax: A single center experience.
Maples KT; Nooka AK; Gupta V; Joseph NS; Heffner LT; Hofmeister C; Dhodapkar M; Matulis SM; Lonial S; Boise LH; Kaufman JL
Am J Hematol; 2021 Mar; 96(3):E68-E71. PubMed ID: 33275813
[No Abstract] [Full Text] [Related]
16. Venetoclax in upfront induction therapy for primary plasma cell leukemia with t(11;14) or BCL2 expression.
Roy T; An JB; Doucette K; Chappell AM; Vesole DH
Leuk Lymphoma; 2022 Mar; 63(3):759-761. PubMed ID: 35076333
[No Abstract] [Full Text] [Related]
17. Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo.
Zhou L; Zhang Y; Sampath D; Leverson J; Dai Y; Kmieciak M; Nguyen M; Orlowski RZ; Grant S
Br J Cancer; 2018 Feb; 118(3):388-397. PubMed ID: 29241222
[TBL] [Abstract][Full Text] [Related]
18. Biologic Implications of t(11;14) in Multiple Myeloma Explained With a Case of Refractory Disease Sensitive to Venetoclax.
Soleimani A; Koka M; Singh ZN; Kesari V; Badros A
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):e556-e559. PubMed ID: 32653454
[No Abstract] [Full Text] [Related]
19. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma.
Touzeau C; Dousset C; Le Gouill S; Sampath D; Leverson JD; Souers AJ; Maïga S; Béné MC; Moreau P; Pellat-Deceunynck C; Amiot M
Leukemia; 2014 Jan; 28(1):210-2. PubMed ID: 23860449
[No Abstract] [Full Text] [Related]
20. How do we manage t(11;14) plasma cell disorders with venetoclax?
Chakraborty R; Bhutani D; Lentzsch S
Br J Haematol; 2022 Oct; 199(1):31-39. PubMed ID: 35594184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
